Eli Lilly & Co. (LLY)
Trading Center
Loading...
Symbols:
LLY Forum Topics
- All Comments on LLY
- General Discussion on LLY
- Looking Inside the New Ben Graham ETN Baskets [view article]
- Time to Invest in Pharmaceuticals? [view article]
- Four Drug Companies Vying for Diabetes Patients [view article]
- 5 Potential Buyout Targets in Biotech - Barron's [view article]
- Out of the Money - Midday Fast Money (8/12/08) [view article]
- Eli Lilly Sells Lab Site to Covance [view article]
- Oncology Conference Countdown: What Will Pharma and Biotech Companies Report? [view article]
- ADA's 68th Scientific Sessions: A New Look at Insulin Therapy [view article]
- Watch for More Coming Biotech Acquisitions [view article]
- PowerShares FTSE RAFI Healthcare: Big Bets on Dow Dogs [view article]
- Wall Street Breakfast: Must-Know News [view article]
- They All Fall Dow - Fast Money Recap (6/2/08) [view article]
loading ...Recent LLY Articles
- AstraZeneca Gives FluMist Spray a Shot in the Arm
- Looking Inside the New Ben Graham ETN Baskets
- Time to Invest in Pharmaceuticals?
- Four Drug Companies Vying for Diabetes Patients
- 5 Potential Buyout Targets in Biotech - Barron's
- Out of the Money - Midday Fast Money (8/12/08)
- China Biotech Week in Review: Earnings and More
- Eli Lilly Sells Lab Site to Covance
- Watch for More Coming Biotech Acquisitions
- Wall Street Breakfast: Must-Know News
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Looking Inside the New Ben Graham ETN Baskets [view article]
I do appreciate the commentary from everyone.Mr. Carson, I especially appreciate your commentary regarding some dividend paying ETNs. The unique features of some of these ETNs are certainly worth exploring. Thanks again! Reply
Time to Invest in Pharmaceuticals? [view article]
Where does everyone get this $800-1000M per drug number? From the pharmaceuticals themselves of course!Can that number be fully trusted? Reply
Looking Inside the New Ben Graham ETN Baskets [view article]
GREAT article! Thank you, very informative!Reply
ah
Looking Inside the New Ben Graham ETN Baskets [view article]
Just buy the S&P 500, this ETN will do no better than the overall index in my opinion ReplyCarson
Looking Inside the New Ben Graham ETN Baskets [view article]
Rick...Excellent article about ETNs!Just to clarify, however, there actually ARE 4 ETN's which currently do(or are planning to) pay dividends. (You had mentioned that "ETNs don't pay dividends, interest or capital gains")
The four ETNs which pay dividends are GCE (Goldman Sacks-Claymore CEF Index Linked ETN), BSR (BearLinx Alerian MPL Select ETN) ,PGD (Barclays Asian and Gulf Currency Revaluation ETN) and JEM (Barclays GEMS Index ETN).
GCE invests in a basket of 75 discounted Closed-End Funds following a CEF Index selected by Claymore Securities (claymoresecurities.com). GCE's distribution rate is variable with the past three quarterly dividends being $1.66, $0.28 and $0.64.
BSR is an energy infrastructure play which invests in fifty Master Limited Partnerships (MLPs) which track the "Alerian MPL Select Index" (alerian.com). One unique feature of this ETN is its issuance of a 1099 at year end, rather than the K-1 Partnership tax reports normally associated with individual MLP holdings.
Both PGD and JEM are currencies bundles pegged, to some extent, to the US Dollar, and were just recently brought to market by Barclays on June 18, 2008. PGD includes currencies of the Saudi Arabian riyal, Hong Kong dollar, United Arab Emirates dirham, Singaporean dollar and the Chinese yuan. The GEM bundle will include currency holdings from 15 Global Emerging Markets (hence the symbol, GEM) in Eastern Europe, the Middle East, Africa, Latin America an Asia. Both PGD and GEM will distribute interest earned on the locally earned currency deposits on a quarterly basis. The rates are yet to be determined. (ipathetn.com) Reply
Four Drug Companies Vying for Diabetes Patients [view article]
Hi GreenClay,Generex has conducted dose-response studies on their buccal insulin spray. Their patented Rapidmist delivery device has been found to bring precision dosing where each spray measures approx 1 Unit- of Oral-lyn human insulin from the first spray to the last. This allows for tight titration and is one of the main positive features of Oral-lyn. If you email the company at generex.com, they can send you the published data from the peer review (I believe the report was dated 2005).
There are no pills or syrup this far along in Phase testing. Oramed and Biocon have pills that are in very early Phase IIa, and one has a pill whose dose measures 8 mg and the other measures 10 mg. Both have tested their pills in a small handful of patients. I have followed both, and Emisphere also has promising platform technology, but has had difficulties in translating their research into a successful pill form.
Exubera was also measured in mg, and not the unit that diabetics, such as yourself, are familiar with. Their dosing was confusing and one of the many reasons for its lack of success.
An effective oral one unit dose should make things easier to calculate, depending on weight and carbs per meal. The low dose aspect would be a negative if many units are required for certain Type 1's. It is interesting that Generex is set to begin a diabetes preventive trial for those that are pre-diabetic or at risk of developling diabetes. This is similar to TrialNet, and is an area to watch for future developments. Reply
5 Potential Buyout Targets in Biotech - Barron's [view article]
Years ago, I thought that I could divine the future of the biotech companies. Account damaging stock gaps from failed “sure thing” phase–three studies and unexpected drug side-effects required a reassessment of how to successfully invest in the sector. Fortunately, before long I realized that foretelling a novel compound’s efficacy and long term safety was beyond my prophetic ability.Most industry group sub-sectors have a high price change correlation among component companies; however this is not the case with biotechnology. This characteristic suggests that a shotgun approach will be a logical path to success.
The biotech industry in aggregate creates many successful marketable compounds, with ensuing product profits much greater than the sum of cash burn, and long safety issues with resultant litigation expenses, etc. Thus, a more effective way to gain exposure is by using an eight stock or greater basket, or an ETF; select an ETF carefully though, as company weighting methodologies can vary greatly among ETF managers. For example, currently BBH has a huge 39.5% allocation to DNA, whereas XBI has a maximum of 6.1% in any one company. Also, as you would expect, with diversification we can expect a less-wild ride; using daily closing price, the sixty-day standard deviation of XBI is 25.7%, whereas the same for BIIB is 83%, and for ELN a gut-wrenching 209.2%.
Reply
Four Drug Companies Vying for Diabetes Patients [view article]
As a major biotech investor and as a diabetic who has been on insulin for 23 years allow me to add my 2 cents.Oral insulin sprays may be effectively absorbed but how one titrates the insulin is beyond my ken. As someone who regularly monitors his blood glucose (BG) using at least 7 test strips a day to accomplish this I know how difficult a task it is to have ones hemoglobin A1C approach normal which is how I've survived so far without any major diabetic encumbrances.
Oral insulin (tablets or syrup) can be measured, sprays are very difficult. Reply
furgeson
5 Potential Buyout Targets in Biotech - Barron's [view article]
NOVA, I couldn't have said it any better. Bravo! ReplyTime to Invest in Pharmaceuticals? [view article]
User 245013 - I'm not a journalist. And yes I am aware that it takes many years of research and hundreds of millions in development costs to bring a drug to market. Certainly many drugs remain unprofitable for many years, and sometimes their entire lifetime post-launch.Hence why many large pharmas are acquiring or partnering with research facilities and other drug companies. Reply
Time to Invest in Pharmaceuticals? [view article]
Howard,Good article, except for one point. It takes about $1 billion to get a drug launced AND THEN it costs a few pennies to produce. Just trying to keep you journalists honest (a toughjob nowadays). Reply
Four Drug Companies Vying for Diabetes Patients [view article]
DMYDY, Pink sheets, advanced stage potential Type 1 cure, highly illiquid put in a bid about $1 above last indicated trade for up to 500 shares, try to buy more and you will drive the price up by your lonesome. ReplyTime to Invest in Pharmaceuticals? [view article]
Everyone wants universal healthcare, inexpensive/affordable healthcare and quality healthcare. You can only have two of them at any one time. To increase one it is at the expense of one or both of the other two. More and more doctors are beginning to refuse government sponsored health care programs, e.g. Medicare. Too much paperwork and too little pay. ReplyTime to Invest in Pharmaceuticals? [view article]
one of my major concerns about this upcoming year is how the election will pan out. If universal healthcare turns out to be a real possibility, then pharma companies are going to find it even tougher as their biggest customer will be the government. ReplyFour Drug Companies Vying for Diabetes Patients [view article]
Gnbt:: a possible buy out candidate. Reply